イヌの薬物代謝の個体差における原因の一端を解明~CYP2B6解析でヒトやイヌの安全な薬物治療の発展に貢献~

ad

2025-10-29 理化学研究所,鹿児島大学,昭和薬科大学,東京大学,日本動物高度医療センター,ITEA株式会社東京環境アレルギー研究所,麻布大学

理化学研究所・鹿児島大学などの共同研究チームは、119犬種6,344頭のゲノムを解析し、イヌの主要薬物代謝酵素CYP2B6遺伝子に11種の遺伝的バリアントを同定した。特に、275番目のグルタミン酸欠失や145番目のアミノ酸置換が麻酔薬プロポフォールの代謝能を変化させることを実験的に確認。分子ドッキング解析により、還元酵素部位の構造変化が活性低下を招くことが示唆された。本成果は、犬種間での薬物代謝差の遺伝的要因を初めて大規模に明らかにしたもので、ヒトの個別化医療や創薬にも応用可能な知見である。論文は『Drug Metabolism and Disposition』誌に掲載。

イヌの薬物代謝の個体差における原因の一端を解明~CYP2B6解析でヒトやイヌの安全な薬物治療の発展に貢献~
本研究の概要

<関連情報>

6344匹の犬のスクリーニングによって同定 Genetic variants of cytochrome P450 2C21 identified by screening 6344 dogs influenced oxidations of the probe drug omeprazole

Yasuhiro Uno, Koya Fukunaga, Genki Ushirozako, Norie Murayama, Keijiro Mizukami, Tomomi Aoi, Hirotaka Tomiyasu, Muneki Honnami, Hajime Tsujimoto, Masahiro Sakaguchi, Masaharu Hisasue, Taisei Mushiroda, Yukihide Momozawa  Hiroshi Yamazaki
Biochemical Pharmacology  Available online: 3 October 2025
DOI:https://doi.org/10.1016/j.bcp.2025.117394

Abstract

The cytochromes P450 (P450s or CYPs) are essential drug-metabolizing enzymes. In humans, the variability in metabolic activity is partly accounted for by genetic variants of the responsible P450. However, P450 genetic variants remain largely to be investigated in dogs, a species often used in drug metabolism studies. In this study, the sequencing of 6344 dog genomes found five CYP2C21 variants, including three missense variants (p.K119Q, p.R125C, and p.R329H), one synonymous variant, and one frameshift variant (c.669dupA). The latter creates a premature termination codon that results in the elimination of the heme-binding region and substrate recognition sites 3–6; these are important functional domains, and thus c.669dupA is considered to be a null allele. Some of these variants were found only in a limited number of dogs and breeds, indicating that their distribution may be restricted. Recombinant proteins of the missense variants, co-expressed with NADPH-P450 reductase, were prepared in Escherichia coli for metabolic assays. The CYP2C21 R125C variant showed decreased metabolic capacity compared with the wild-type CYP2C21 protein. These results suggest the possible contribution of genetic variants of CYP2C21 to the variability of drug metabolism in dogs.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました